OncoMatch/Clinical Trials/NCT05620290
MRI-Guided Focused Ultrasound Radiosensitization for Patients With Malignant Melanoma and Non Melanoma Skin Cancer
Is NCT05620290 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Definity and Sonalleve Focused Ultrasound Device for melanoma.
Treatment: Definity · Sonalleve Focused Ultrasound Device — The objective of this study is to examine the safety profile and therapeutic efficacy of MRI-guided focused ultrasound microbubble therapy and radiotherapy in humans.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Disease stage
Required: Stage I, II, III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunotherapy
Patient on immunotherapy.
Lab requirements
Kidney function
Creatinine within normal institutional limits or creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above the institutional upper limit of normal. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded]
Cardiac function
No severe cardiovascular disease, unstable hemodynamics, myocardial infarction within six months, unstable angina, congestive heart failure, ejection fraction < 50%, cardiac shunts, cardiac arrhythmia, cardiac pacemaker, or severe hypertension (diastolic BP > 100 mmHg)
Severe cardiovascular, neurological, renal or hematological chronic disease. Cardiac disease or unstable hemodynamics, including myocardial infarction within six months, unstable angina, congestive heart failure, ejection fraction < 50%, cardiac shunts, cardiac arrhythmia and cardiac pacemaker. Severe hypertension (diastolic BP > 100 mmHg). Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify